PEAR vs. UPHL, ENSC, SNGX, TCON, ARTL, GBNHF, HILS, PRTG, ZVSA, and HSDT
Should you be buying Pear Therapeutics stock or one of its competitors? The main competitors of Pear Therapeutics include UpHealth (UPHL), Ensysce Biosciences (ENSC), Soligenix (SNGX), TRACON Pharmaceuticals (TCON), Artelo Biosciences (ARTL), Greenbrook TMS (GBNHF), Hillstream BioPharma (HILS), Portage Biotech (PRTG), ZyVersa Therapeutics (ZVSA), and Helius Medical Technologies (HSDT). These companies are all part of the "medical" sector.
UpHealth (NYSE:UPHL) and Pear Therapeutics (NASDAQ:PEAR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
UpHealth has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Pear Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Pear Therapeutics received 10 more outperform votes than UpHealth when rated by MarketBeat users.
UpHealth has a net margin of -44.49% compared to UpHealth's net margin of -594.70%. Pear Therapeutics' return on equity of 36.86% beat UpHealth's return on equity.
In the previous week, Pear Therapeutics' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.
UpHealth has higher revenue and earnings than Pear Therapeutics. UpHealth is trading at a lower price-to-earnings ratio than Pear Therapeutics, indicating that it is currently the more affordable of the two stocks.
56.1% of UpHealth shares are held by institutional investors. Comparatively, 71.2% of Pear Therapeutics shares are held by institutional investors. 34.2% of UpHealth shares are held by insiders. Comparatively, 30.7% of Pear Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
UpHealth beats Pear Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Pear Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PEAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PEAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pear Therapeutics Competitors List
Related Companies and Tools
